Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin + fluoxetine is a combination of two agents—curcumin, the principal active component of the spice turmeric (Curcuma longa), and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant. This combination has been investigated for its potential synergistic effects in treating major depressive disorder (MDD). Curcumin exhibits antidepressant-like activity in animal models, possibly through modulation of monoaminergic neurotransmission, anti-inflammatory effects via reduction of proinflammatory cytokines, enhancement of neurogenesis in the hippocampus, and upregulation of brain-derived neurotrophic factor (BDNF)[1][4][5][6][8]. Fluoxetine acts primarily by inhibiting serotonin reuptake at synaptic clefts. Clinical studies suggest that while both agents individually have antidepressant effects comparable to each other and to standard therapy with imipramine or SSRIs alone[1][4][5], their combination may increase response rates but does not significantly enhance efficacy over monotherapy[1][4]. The safety profile appears favorable; however, moderate drug interaction risk exists due to possible pharmacodynamic interactions such as increased bleeding risk when combined[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + fluoxetine.